IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Zacks09-09

Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466193492?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28","is_english":true,"pubTime":"2024-09-09 20:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466193492","market":"us","top_or_hot":-1,"title":"IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab","media":"Zacks","content":"<div>\n<p>Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being ...</p>\n\n<a href=\"https://finance.yahoo.com/news/imvt-stock-upbeat-data-graves-123500299.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-09 20:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/imvt-stock-upbeat-data-graves-123500299.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being ...</p>\n\n<a href=\"https://finance.yahoo.com/news/imvt-stock-upbeat-data-graves-123500299.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/imvt-stock-upbeat-data-graves-123500299.html","article_id":"2466193492","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466193492","pubTimestamp":1725885300,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves’ Disease .IMVT’s Batoclimab Shows Superior Efficacy in GD Patients. The enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs  therapy.Patients were then treated with the high batoclimab dose, 680 mg weekly subcutaneous injection , for 12 weeks, followed by another 12 weeks of lower batoclimab dose, 340 mg weekly SC.Apart from the GD study, separate mid to late-stage studies are also currently ongoing, evaluating batoclimab for the treatment of other autoimmune indications, like Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and thyroid eye disease. Subject to positive data from these studies, Immunovant plans to study IMVT-1402 for each of the above ind","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","KRYS":"Krystal Biotech Inc.","BK4566":"资本集团","BK4187":"航天航空与国防","BK4516":"特朗普概念","ILMN":"Illumina","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","IMVT":"Immunovant, Inc.","FULC":"Fulcrum Therapeutics","BK4121":"生命科学工具和服务","GD":"通用动力","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4588":"碎股"},"translate_title":"IMVT储备了Batoclimab格雷夫斯病研究的乐观数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1,"IMVT":1,"ILMN":1,"GD":1,"FULC":1},"content_text":"Shares of Immunovant IMVT are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves’ Disease (GD).\nIMVT’s Batoclimab Shows Superior Efficacy in GD Patients\nThe enrolled patient population of the phase IIa study of batoclimab comprised uncontrolled GD patients who were hyperthyroid despite anti-thyroid drugs (ATD) therapy. Patients were then treated with the high batoclimab dose, 680 mg weekly subcutaneous injection (SC), for 12 weeks, followed by another 12 weeks of lower batoclimab dose, 340 mg weekly SC.\nThe data showed that treatment with the batoclimab 680 mg dose led to a mean Immunoglobin G (IgG) reduction of 77%, translating to a Response rate of 76% in the GD patient population after 12 weeks. Additionally, it was observed that at the end of the first 12 weeks, 56% of the patients treated with the high-dose of the candidate achieved an ATD-Free Response.\nDuring the next 12 weeks of treatment with the batoclimab 340 mg dose, the mean IgG level was further reduced by 65%, with a correspondingly lower responder rate of 68%. Additionally, the ATD-Free Response rate dropped to 36% in the second 12 weeks.\nPatients who experienced at least a 70% IgG reduction by the end of the study had an ATD-Free Response rate nearly three times higher than those who did not (60% and 23%, respectively).\nYear to date, shares of Immunovant have plunged 19.2% compared with the industry’s 2.8% decline.\nImage Source: Zacks Investment Research\nAlong with the data readout, Immunovant also revealed data from multiple proprietary market research studies, highlighting a persistent unmet need among patients treated with ATDs who are either intolerant to, uncontrolled or have relapsed after treatment with the same.  \nPer IMVT, real-world claims data shows that 25-30% of GD patients remain uncontrolled on ATDs each year, with few treatment options available. This presents a valuable commercial opportunity for the company with little competition.\nIMVT’s Future Development Plans in Autoimmune Diseases\nLeveraging the encouraging results from the phase IIa GD study ofbatoclimab, Immunovant is currently gearing up to initiate a pivotal study of its lead candidate, IMVT-1402, a novel and fully-human monoclonal antibody, for the same indication by the end of 2024.\nIn the press release, the company has also announced that it has aligned with the FDA regarding the impending pivotal study design and secured investigational new drug application clearance for IMVT-1402 to treat GD.\nApart from the GD study, separate mid to late-stage studies are also currently ongoing, evaluating batoclimab for the treatment of other autoimmune indications, like Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and thyroid eye disease. Subject to positive data from these studies, Immunovant plans to study IMVT-1402 for each of the above indications.\nThe company is on track to initiate four to five potentially registrational programs for IMVT-1402 over the next fiscal year (ending March 31, 2025). Over the next two fiscal years, the company plans to initiate studies in a total of 10 indications for IMVT-1402. The company also expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies.\n\nImmunovant, Inc. Price and Consensus\n\nImmunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote\n\nZacks Rank & Stocks to Consider\nImmunovant currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the biotech sector are Illumina, Inc. ILMN, Krystal Biotech, Inc. KRYS and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10,7%.\nILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.\nIn the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.5%.\nKRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.\nIn the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.5%.\nFULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nIllumina, Inc. (ILMN) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nImmunovant, Inc. (IMVT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466193492"}